Earlier on Thursday, the company published data that showed its next-generation shot, CV2CoV, produced neutralizing antibodies in monkeys that were comparable to those produced by Pfizer Inc's approved vaccine. The efficacy was also greater than the company's first-generation vaccine, it added.
CureVac’s shot was highly anticipated as unlike other mRNA vaccines, it can be stored in regular refrigerators and remains stable for 24 hours at room temperature.
Agreements with Celonic Group of Switzerland and Germany's Wacker would be terminated but existing production deals with Rentschler Biopharma and Novartis would remain unchanged, CureVac said in a statement.
The encouraging news on its "second-generation" vaccine gave CureVac's German-listed shares an 8% lift, as the stock gradually recovers from a slump in June when the German biotech company's first vaccine candidate recorded a disappointing 48% efficacy in mass testing on humans.
The announcement comes a week after CureVac, a German biotech firm, said its Covid-19 vaccine was only 47% effective in a late-stage trial, missing the study's main goal and casting doubt on the potential delivery of hundreds of millions of doses to the EU.
German biotech firm CureVac' vaccine proved only 47% effective in an initial trial read-out.
EMA said it will consider the benefits and the risks demonstrated by the vaccine and come up with a decision on whether the vaccine can be approved or not.
CureVac initially expected to seek European approval for its jab in the second quarter, with Germany pencilling in 1.4 million doses by end-June.
The trial, which aims to recruit nearly 3,000 participants, will look at seven different Covid-19 shots, some of which are already approved by regulators and in wide use and others that are still in development. British officials have been planning for the possibility of a booster vaccination campaign before the winter after initially targeting immunisation with a two-dose schedule for the whole adult population by the summer.
It would be good to have vaccines that can fight any coronavirus ready in advance.
A pan-European consortium developing a Covid-19 vaccine is in talks with big pharma to support the late-stage development of its shot and ramp up manufacturing, the head of German biotech firm Leukocare told Reuters.
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
